Monday, June 27, 2022
No menu items!
HomeHealth SciencePharmacotherapy vs. minimally invasive therapies as preliminary remedy for moderate-to-severe benign prostatic...

Pharmacotherapy vs. minimally invasive therapies as preliminary remedy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness examine

[ad_1]

  • Roehrborn CG, Marks L, Harkaway R. Enlarged prostate: a landmark nationwide survey of its prevalence and affect on US males and their companions. Prostate Most cancers Prostatic Dis. 2006;9:30–4.

    CAS 
    Article 

    Google Scholar
     

  • Egan KB. The epidemiology of benign prostatic hyperplasia related to decrease urinary tract signs: prevalence and incident charges. Urol Clin North Am. 2016;43:289–97.

    Article 

    Google Scholar
     

  • Wei JT, Calhoun E, Jacobsen SJ. Urologic illnesses in America venture: benign prostatic hyperplasia. J Urol. 2008;179:S75–80.

    PubMed 

    Google Scholar
     

  • Taub DA, Wei JT. The economics of benign prostatic hyperplasia and decrease urinary tract signs in the US. Curr Urol Rep. 2006;7:272–81.

    Article 

    Google Scholar
     

  • Nickel JC, Aaron L, Barkin J, Elterman D, Nachabe M, Zorn KC. Canadian Urological Affiliation guideline on male decrease urinary tract signs/benign prostatic hyperplasia (MLUTS/BPH): 2018 replace. Can Urol Assoc J. 2018;12:303–12.

    Article 

    Google Scholar
     

  • Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Administration of decrease urinary tract signs attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical administration. J Urol. 2021;206:806–17.

    Article 

    Google Scholar
     

  • Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Administration of decrease urinary tract signs attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-surgical analysis and therapy. J Urol. 2021;206:818–26.

    Article 

    Google Scholar
     

  • Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug adherence and medical outcomes for sufferers underneath pharmacological remedy for decrease urinary tract signs associated to benign prostatic hyperplasia: population-based cohort examine. Eur Urol. 2015;68:418–25.

    Article 

    Google Scholar
     

  • Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to drugs for benign prostatic hyperplasia. J Urol. 2009;181:2214–21.

    Article 

    Google Scholar
     

  • Roehrborn CG, Siami P, Barkin J, Damiao R, Main-Walker Ok, Nandy I, et al. The results of mixture remedy with dutasteride and tamsulosin on medical outcomes in males with symptomatic benign prostatic hyperplasia: 4-year outcomes from the CombAT examine. Eur Urol. 2010;57:123–31.

    CAS 
    Article 

    Google Scholar
     

  • Alexander CE, Scullion MM, Omar MI, Yuan Y, Mamoulakis C, N’Dow JM, et al. Bipolar versus monopolar transurethral resection of the prostate for decrease urinary tract signs secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019;12:CD009629.

    PubMed 

    Google Scholar
     

  • Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R. The affect of minimally invasive surgical procedures for the therapy of symptomatic benign prostatic hyperplasia on male sexual perform: a scientific assessment. Asian J Androl. 2010;12:500–8.

    Article 

    Google Scholar
     

  • Zang YC, Deng XX, Yang DR, Xue BX, Xu LJ, Liu XL, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a scientific assessment with meta-analysis of randomized managed trials. Lasers Med Sci. 2016;31:235–40.

    Article 

    Google Scholar
     

  • Sokolakis I, Pyrgidis N, Russo GI, Sountoulides P, Hatzichristodoulou G. Preserving ejaculation: a information via the panorama of interventional and surgical choices for benign prostatic obstruction. Eur Urol Focus. 2022. https://doi.org/10.1016/j.euf.2022.03.008.

  • Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic assessment of decrease urinary tract signs/benign prostatic hyperplasia surgical remedies on males’s ejaculatory perform: time for a bespoke method? Int J Urol. 2016;23:22–35.

    Article 

    Google Scholar
     

  • Lokeshwar SD, Patel P, Shah SM, Ramasamy R. A scientific assessment of human trials utilizing stem cell remedy for erectile dysfunction. Intercourse Med Rev. 2020;8:122–30.

    Article 

    Google Scholar
     

  • Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral carry for the therapy of decrease urinary tract signs related to prostate enlargement because of benign prostatic hyperplasia: the L.I.F.T. examine. J Urol. 2013;190:2161–7.

    Article 

    Google Scholar
     

  • Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. 5 yr outcomes of the potential randomized managed prostatic urethral L.I.F.T. examine. Can J Urol. 2017;24:8802–13.

    PubMed 

    Google Scholar
     

  • McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel Ok, Shore ND, et al. Minimally invasive prostate convective water vapor power ablation: a multicenter, randomized, managed examine for the therapy of decrease urinary tract signs secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529–38.

    Article 

    Google Scholar
     

  • McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal remedy for decrease urinary tract signs related to benign prostatic hyperplasia: 4-year outcomes from randomized managed examine. Urology. 2019;126:171–9.

    Article 

    Google Scholar
     

  • Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Massive, multi-center, potential registry of rezum water vapor remedy for benign prostatic hyperplasia. Urology. 2022. https://doi.org/10.1016/j.urology.2022.02.001.

    Article 
    PubMed 

    Google Scholar
     

  • Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Rezum remedy for >/=80-mL benign prostatic enlargement: a big, multicentre cohort examine. BJU Int. 2022. https://doi.org/10.1111/bju.15753.

    Article 
    PubMed 

    Google Scholar
     

  • Mollengarden D, Goldberg Ok, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal remedy for benign prostatic hyperplasia: a single workplace expertise. Prostate Most cancers Prostatic Dis. 2018;21:379–85.

    Article 

    Google Scholar
     

  • Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgical procedure as preliminary remedy for sufferers with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness evaluation. BJU Int. 2018;122:879–88.

    Article 

    Google Scholar
     

  • Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Suggestions for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in well being and drugs. JAMA. 2016;316:1093–103.

    Article 

    Google Scholar
     

  • TreeAge Professional 2021, R1.0. TreeAge Software program, Williamstown, MA; Software program accessible at https://www.treeage.com.

  • Tanneru Ok, Jazayeri SB, Alam MU, Kumar J, Bazargani S, Kuntz G, et al. An oblique comparability of newer minimally invasive remedies for benign prostatic hyperplasia: a community meta-analysis mannequin. J Endourol. 2021;35:409–16.

    Article 

    Google Scholar
     

  • Guo S, Muller G, Lehmann Ok, Talimi S, Bonkat G, Puschel H, et al. The 80-W KTP GreenLight laser vaporization of the prostate versus transurethral resection of the prostate (TURP): adjusted evaluation of 5-year outcomes of a potential non-randomized bi-center examine. Lasers Med Sci. 2015;30:1147–51.

    Article 

    Google Scholar
     

  • Mattiasson A, Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, et al. 5-year follow-up of suggestions microwave thermotherapy versus TURP for medical BPH: a potential randomized multicenter examine. Urology. 2007;69:91–6.

    Article 

    Google Scholar
     

  • Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Pure historical past of prostatism: longitudinal modifications in voiding signs in neighborhood dwelling males. J Urol. 1996;155:595–600.

    CAS 
    Article 

    Google Scholar
     

  • McVary KT, Gittelman MC, Goldberg KA, Patel Ok, Shore ND, Levin RM, et al. Remaining 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal remedy for therapy of average to extreme decrease urinary tract signs secondary to benign prostatic hyperplasia. J Urol. 2021;206:715–24.

    Article 

    Google Scholar
     

  • Bachmann A, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A European multicenter randomized noninferiority trial evaluating 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the therapy of benign prostatic obstruction: 12-month outcomes of the GOLIATH examine. J Urol. 2015;193:570–8.

    Article 

    Google Scholar
     

  • Thomas JA, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A multicenter randomized noninferiority trial evaluating GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the therapy of benign prostatic obstruction: two-yr outcomes of the GOLIATH examine. Eur Urol. 2016;69:94–102.

    Article 

    Google Scholar
     

  • Castellani D, Pirola GM, Rubilotta E, Gubbiotti M, Scarcella S, Maggi M, et al. GreenLight laser photovaporization versus transurethral resection of the prostate: a scientific assessment and meta-analysis. Res Rep Urol. 2021;13:263–71.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Teng J, Zhang D, Li Y, Yin L, Wang Ok, Cui X, et al. Photoselective vaporization with the inexperienced gentle laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a scientific assessment and meta-analysis. BJU Int. 2013;111:312–23.

    Article 

    Google Scholar
     

  • McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr., Dixon CM, Kusek JW, et al. The long-term impact of doxazosin, finasteride, and mixture remedy on the medical development of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.

    CAS 
    Article 

    Google Scholar
     

  • Arias E, Xu J. Nationwide Very important Statistics Stories. United States Life Tables, 2018. Vol. 69, Quantity 12, p. 45. Facilities for Illness Management and Prevention; 2020.

  • Baladi JF, Menon D, Otten N. An financial analysis of finasteride for therapy of benign prostatic hyperplasia. Pharmacoeconomics. 1996;9:443–54.

    CAS 
    Article 

    Google Scholar
     

  • Ackerman SJ, Rein AL, Blute M, Beusterien Ok, Sullivan EM, Tanio CP, et al. Value effectiveness of microwave thermotherapy in sufferers with benign prostatic hyperplasia: half I-methods. Urology. 2000;56:972–80.

    CAS 
    Article 

    Google Scholar
     

  • Liu H, Harris KM, Weinberger S, Serxner S, Mattke S, Exum E. Impact of an employer-sponsored well being and wellness program on medical value and utilization. Popul Well being Manag. 2013;16:1–6.

    CAS 
    Article 

    Google Scholar
     

  • US Facilities for Medicare and Medicaid Providers. Medicare half D drug spending dashboard & information. 2021. https://www.cms.gov/Analysis-Statistics-Information-and-Techniques/Statistics-Traits-and-Stories/Data-on-Prescription-Medicine/MedicarePartD.

  • Black L, Naslund MJ, Gilbert TD, Davis AE, Ollendorf DA. An examination of therapy patterns and prices of care amongst sufferers with benign prostatic hyperplasia. Am J Manag Care. 2006;12:S99–110.

    PubMed 

    Google Scholar
     

  • Chughtai B, Rojanasarot S, Neeser Ok, Gultyaev D, Amorosi SL, Shore ND. Value-effectiveness and price range affect of rising minimally invasive surgical remedies for benign prostatic hyperplasia. J Well being Econ Outcomes Res. 2021;8:42–50.

    Article 

    Google Scholar
     

  • Nationwide Institue for Well being and Care Excellence. Rezum for treating decrease urinary tract signs secondary to benign prostatic hyperplasia. Medical applied sciences steering. 2020. www.good.org.uk.steering/mtg49.

  • Ulchaker JC, Martinson MS. Value-effectiveness evaluation of six therapies for the therapy of decrease urinary tract signs because of benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43.

    Article 

    Google Scholar
     

  • Robert G, Cornu JN, Fourmarier M, Saussine C, Descazeaud A, Azzouzi AR, et al. Multicentre potential analysis of the training curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016;117:495–9.

    Article 

    Google Scholar
     

  • Robles J, Pais V, Miller N. Thoughts the gaps: adoption and underutilization of holmium laser enucleation of the prostate in the US from 2008 to 2014. J Endourol. 2020;34:770–6.

  • US Facilities for Medicare and Medicaid Providers. FY 2019 IPPS Remaining Rule Residence Web page. 2021. https://www.cms.gov/Medicare/Medicare-Charge-for-Service-Cost/AcuteInpatientPPS/FY2019-IPPS-Remaining-Rule-Residence-Web page-Gadgets/FY2019-IPPS-Remaining-RuleTables.html.

  • [ad_2]

    RELATED ARTICLES

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Most Popular

    Recent Comments